Abeona Therapeutics Inc.

NasdaqCM ABEO

Abeona Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -10.20%

Abeona Therapeutics Inc. Gross Profit Margin is -10.20% for the Trailing 12 Months (TTM) ending September 30, 2024, a -136.72% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Abeona Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 27.77%, a -28.45% change year over year.
Abeona Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 38.82%, a 112.24% change year over year.
Abeona Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -317.03%, a 5.57% change year over year.
Abeona Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -335.73%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: ABEO

Abeona Therapeutics Inc.

CEO	Dr. Vishwas Seshadri M.B.A., Ph.D.
IPO Date	Sept. 19, 1980
Location	United States
Headquarters	1330 Avenue of the Americas
Employees	84
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Key trends

Past 5 years